Development of NET theranosptic agents based on novel 64Cu-labeled somatostatin derivatives
| Project/Area Number |
15K19824
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Radiation science
|
|---|
| Research Institution | Suzuka University of Medical Science |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2017-03-31
|
| Project Status |
Completed (Fiscal Year 2016)
|
| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2016: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
|---|
| Keywords | 神経内分泌腫瘍 / ソマトスタチン誘導体 / 64Cuキレーター / ATSM誘導体 / 診断／治療薬開発 / 診断／治療用薬剤開発 |
|---|
| Outline of Final Research Achievements |
Radiolabeled somatostatin (SST) analogues are useful for diagnosis and therapy of neuroendcrine tumor (NET). The aim of this study is to develop a novel theranostic agent which enables to perform both diagnosis and therapy of NET, we designed and synthesized novel Cu-64-labeled SST analogues. Administration of them in the model mice implanted AR42J cells before acquiring time-dependent PET images contributed to obtain clear tumor images. In addition, higher accumulation of Cu-64 over a prolonged period to AR42J tumor were observed in mice administrated a novel radiolabeled SST than in mice administrated a reference SST analogue. These results suggest the usability of Cu-64-labeled SST analogue as a novel agent for NET diagnosis.
|
Report
(3 results)
Research Products
(2 results)
